Literature DB >> 23709679

Should platelet function testing guide antiplatelet therapy for patients with coronary artery stenting or acute coronary syndromes?

Kevin P Cohoon1, John A Heit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23709679      PMCID： PMC3926665          DOI： 10.1373/clinchem.2012.200881

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  5 in total

1.  ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.

Authors:  David R Holmes; Gregory J Dehmer; Sanjay Kaul; Dana Leifer; Patrick T O'Gara; C Michael Stein
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

2.  Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study.

Authors:  Jean-Philippe Collet; Guillaume Cayla; Thomas Cuisset; Simon Elhadad; Grégoire Rangé; Eric Vicaut; Gilles Montalescot
Journal:  Am Heart J       Date:  2011-01       Impact factor: 4.749

3.  Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.

Authors:  Nicoline J Breet; Jochem W van Werkum; Heleen J Bouman; Johannes C Kelder; Henk J T Ruven; Egbert T Bal; Vera H Deneer; Ankie M Harmsze; Jan A S van der Heyden; Benno J W M Rensing; Maarten J Suttorp; Christian M Hackeng; Jurriën M ten Berg
Journal:  JAMA       Date:  2010-02-24       Impact factor: 56.272

4.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Authors:  Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol
Journal:  JAMA       Date:  2011-03-16       Impact factor: 56.272

5.  Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.

Authors:  Paul A Gurbel; David Erlinge; E Magnus Ohman; Benjamin Neely; Megan Neely; Shaun G Goodman; Kurt Huber; Mark Y Chan; Jan H Cornel; Eileen Brown; Chunmei Zhou; Joseph A Jakubowski; Harvey D White; Keith A A Fox; Dorairaj Prabhakaran; Paul W Armstrong; Udaya S Tantry; Matthew T Roe
Journal:  JAMA       Date:  2012-11-07       Impact factor: 56.272
  5 in total
  1 in total

1.  Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group.

Authors:  Kevin King; Luanda P Grazette; Dina N Paltoo; John T McDevitt; Samuel K Sia; Paddy M Barrett; Fred S Apple; Paul A Gurbel; Ralph Weissleder; Hilary Leeds; Erin J Iturriaga; Anupama Rao; Bishow Adhikari; Patrice Desvigne-Nickens; Zorina S Galis; Peter Libby
Journal:  JACC Basic Transl Sci       Date:  2016 Jan-Feb
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.